Recent Developments in Mycobacteria-Based Live Attenuated Vaccine Candidates for Tuberculosis

Area of Science:

• Immunology and Infectious Diseases
• Vaccine Development
• Microbiology

Background:

• Tuberculosis (TB) remains a global health challenge, with current Bacillus Calmette-Guerin (BCG) vaccines showing limited efficacy in adults and individuals with compromised immune systems.
• BCG's ineffectiveness against drug-resistant TB and its potential to cause disease in immunocompromised individuals necessitate the development of novel TB vaccine strategies.
• Live attenuated vaccines, such as recombinant BCG (rBCG), are being explored for their potential to elicit broader immune responses without adjuvants.

Purpose of the Study:

• To review recent advancements and identify key research questions in the development of novel mycobacteria-based live attenuated TB vaccine candidates.
• To discuss the utility of mice and rabbits as animal models for evaluating TB vaccine efficacy.
• To highlight the importance of vaccines that can prevent the reactivation of latent Mycobacterium tuberculosis (Mtb) infection (LTBI).

Main Methods:

• Literature review focusing on scientific reports published within the last five years.
• Analysis of the characteristics and potential of novel live attenuated TB vaccine candidates, particularly rBCG.
• Evaluation of the relevance of mouse and rabbit models in preclinical TB vaccine testing.

Main Results:

• Recombinant BCG (rBCG) candidates are emerging as promising alternatives to the current BCG vaccine.
• The development of vaccines targeting latent TB infection (LTBI) is crucial for reducing Mtb transmission.
• Recent research highlights specific features of mice and rabbits that make them valuable models for TB vaccine evaluation.

Conclusions:

• Novel live attenuated TB vaccines, especially rBCG, hold significant potential to overcome the limitations of current BCG vaccination.
• Effective vaccines preventing LTBI reactivation are essential for controlling the spread of tuberculosis.
• Continued research and the strategic use of animal models are vital for advancing TB vaccine development.